Amphastar Pharmaceuticals (AMPH) Q2 2024 earnings summary

Executive summary

• Net revenues for Q2 2024 increased 25% year-over-year to $182.4 million, driven by strong sales of BAQSIMI®, Primatene MIST®, and epinephrine, reflecting a strategic shift toward branded and biosimilar products.

• BAQSIMI® emerged as a key growth driver post-acquisition, with global sales of $38.5 million and direct distribution assumed in the US and parts of Europe.

• Net income for Q2 2024 was $37.9 million ($0.73 per share), up 45% year-over-year; adjusted net income was $48.7 million ($0.94 per share).

• Operational efficiencies, capacity enhancements, and a fully integrated business model supported increased output and market readiness.

• Strategic focus remains on expanding branded, biosimilar, and complex product portfolios, with a diversified pipeline and international presence.

Financial highlights

• Q2 2024 net revenues: $182.4M (+25% YoY); gross margin improved to 52.2% from 49.9% year-over-year, aided by higher-margin product mix.

• Primatene MIST® sales rose 38% to $22.9 million; epinephrine sales surged 67% to $27.9 million, both year-over-year.

• Operating income increased to $55.2 million from $36.9 million in Q2 2023.

• Cash flow from operations for the first six months of 2024 was $124.4 million; $129 million payment made for BAQSIMI® acquisition.

• Adjusted net income margin increased from 3.5% in 2018 to 27.3% in 2023.

Outlook and guidance

• Anticipates three significant product approvals in the second half of 2024: teriparatide (AMP-015), AMP-007, and AMP-002.

• BAQSIMI® projected to reach peak annual sales of $250M–$275M, with incremental adjusted EPS of $2.00–$2.50 at peak.

• Expects continued BAQSIMI® growth and transition to direct distribution in most countries by Q4 2024.

• R&D expenses projected to rise annually due to clinical trials for insulin and inhalation candidates.

• API segment sales expected to remain below historical levels for next two years as major customer qualifies upgraded product.